1 completed, 1 terminated, 1 withdrawn. 2 Phase 2, 1 Not applicable, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Withdrawn 1 |
| Not applicable | 1 | Terminated 1 |
| Phase 1 | 1 | Completed 1 |
Follow Stage III Nasopharyngeal Carcinoma: new trials by email Literature Review of Stage III Nasopharyngeal Carcinoma trials Research Report on Stage III Nasopharyngeal Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer Durvalumab, Epacadostat - Epstein-Barr Virus Positive, Metastatic Nasopharyngeal Carcinoma | Phase 2 | Withdrawn | Alain Algazi | 2020-12-01 | 2020-10-26 | |
| Olfactory Training in Improving Sense of Smell After Radiation Therapy in Patients With Paranasal Sinus or Nasopharyngeal Cancer Physiologic Testing, Quality-of-Life Assessment, Sham Intervention - Stage 0 Nasopharyngeal Carcinoma, Stage 0 Paranasal Sinus Cancer | Not applicable | Terminated | Stanford University | 15 | 2016-12-01 | 2019-02-05 |
| Pembrolizumab and Vorinostat in Treating Patients With Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery Laboratory Biomarker Analysis, Pembrolizumab, Vorinostat - Head and Neck Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma | Phase 1 / Phase 2 | Completed | University of Washington | 50 | 2015-10-08 | 2024-11-26 |
Nasopharyngeal Carcinoma (3) · Nasopharyngeal Neoplasms (1) · Paranasal Sinus Neoplasms (1) · Salivary Gland Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Carcinoma (3) · Head and Neck Neoplasms (3) · Nasopharyngeal Diseases (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms by Site (3) · Neoplasms, Glandular and Epithelial (3) · Otorhinolaryngologic Diseases (3) · Otorhinolaryngologic Neoplasms (3) · Pharyngeal Diseases (3) · Pharyngeal Neoplasms (3) · Stomatognathic Diseases (3) · Nasopharyngeal Neoplasms (2) · Carcinoma, Squamous Cell (1) · Mouth Diseases (1)
Coal Tar (1) · Disulfides (1) · Eucalyptus Oil (1) · Immunoglobulin G (1) · Therapeutics (1) · Vorinostat (1) · durvalumab (1) · epacadostat (1) · pembrolizumab (1)
Alain Algazi (1) · Stanford University (1) · University of Washington (1)
United States (2)
Alain P Algazi, MD (1) · Cristina Rodriguez (1) · Zara Patel (1)
P30CA015704 (1)